The consensus has been collated from estimates submitted by analysts to GSK using a standard template. The information is provided purely for convenience to users of our website, for information ...
Results support potential to address key efficacy and tolerability needs in ROS1-positive NSCLC with US regulatory submission planned in 2026 GSK plc (LSE/NYSE: GSK) today announced positive results ...
GSK plc (LSE/NYSE: GSK) today announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences (Chimagen), a privately held ...
Omjjara approved for use in both newly diagnosed or previously treated myelofibrosis patients Differentiated mechanism of action addresses key manifestations of myelofibrosis, namely anaemia, ...
An estimated 20 million adults aged 50-59 in 30 European countries* have a medical condition that increases their risk for RSV disease 1-3 Authorisation helps protect this population for the first ...
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), ...
GSK plc hosted its annual governance meeting on Tuesday, 11 December 2024. This meeting provided an opportunity to engage with GSK’s investors and share an update on the work of our Board and ...
GSK plc (LSE/NYSE: GSK) and Hansoh Pharma (HKEX: 03692), a Chinese biopharmaceutical company committed to discovering and developing life-changing medicines to help patients conquer serious diseases ...
Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%) Vaccines sales £2.3 billion (+8%) ...
GSK plc (LSE/NYSE: GSK) today announced that Harmony Row Acquisition Co. (“Purchaser”), a direct wholly-owned subsidiary of GlaxoSmithKline LLC (“GSK LLC”), which is an indirect wholly-owned ...
GSK acquires full rights to develop, manufacture and commercialise globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to ...
Luke Miels, Chief Executive Officer, GSK: “GSK has made a strong start to 2026, with good performance from our key growth drivers. Alongside operational delivery, we are focused on execution and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results